GSK and ViiV Healthcare to Present New Infectious Disease Data at IDWeek 2024
TL/DR –
GSK and ViiV Healthcare are to present new data at the Infectious Disease Society of America’s IDWeek 2024. They will present 60 abstracts, showcasing data for vaccines and medicines across a range of infectious diseases, including respiratory syncytial virus (RSV), herpes zoster, uncomplicated urinary tract infections (uUTI), and HIV. GSK’s Chief Scientific Officer declared the company’s focus on pioneering technologies for vaccination and therapeutic solutions, and highlighted GSK’s scientific developments in the prevention and treatment of diseases such as RSV, herpes zoster, uUTI, and HIV.
New Infectious Disease Data from GSK and ViiV Healthcare to be Presented at IDWeek 2024
Global healthcare companies GSK and ViiV Healthcare will be showcasing new data during the Infectious Disease Society of America’s IDWeek 2024. The event will be held in Los Angeles from October 16 to 19, where they will present 60 abstracts, demonstrating their leading approach towards preventative measures against diseases, including respiratory syncytial virus (RSV), herpes zoster, uncomplicated urinary tract infections (uUTI), and HIV.
Vaccines
22 abstracts involving GSK’s innovative pipeline of vaccines will be presented, providing valuable data on the Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) and Shingrix (Zoster Vaccine Recombinant, Adjuvanted). The findings cover a wide demographic spectrum, from older adults to children, on post-marketing safety data, potential risks, and novel methods to combat infectious diseases.
Medicines
13 of the abstracts from GSK’s infectious disease therapeutics portfolio will focus on gepotidacin, a first-in-class oral antibiotic used for treating uUTI and urogenital gonorrhoea (GC). The presentations will examine its efficacy, particularly in patient subgroups suffering from uUTIs with a high unmet need, amidst growing concern over antimicrobial resistance (AMR).
HIV Prevention and Treatment
ViiV Healthcare will present 22 abstracts on their innovative HIV treatment and prevention portfolio, including two oral presentations on real-world evidence from the OPERA and TRIO studies. They will assess the effectiveness of, adherence to, and persistence in using Apretude (cabotegravir long-acting (LA)) for HIV pre-exposure prophylaxis (PrEP) across diverse populations.
Cabotegravir LA for PrEP’s impact on common challenges associated with daily oral PrEP, such as stigma and anxiety, will be highlighted. Furthermore, the benefits, satisfaction, and preference for ViiV’s long-acting and two-drug regimens for HIV treatment will also be discussed, offering insights for healthcare providers to optimize care tailored to individual needs.
For more information on ViiV Healthcare and GSK and their work in infectious diseases, please visit their websites.
Please note that all statements made by GSK, including those in this announcement, are subject to risks and uncertainties that may cause actual results to differ from those projected as described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.
References:
- WHO – Seasonal Influenza Facts
- NIAID – Respiratory Syncytial Virus (RSV)
- CDC – RSV in Older Adults
- WHO – The Global Health Observatory
- Pulingham T., et al. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance, and strategies to overcome. Eur J Pharm Sci. 2022 Mar 1:170:106103.
—
Read More Health & Wellness News ; US News